Statins have been approved to benefit patients underwent percutaneous coronary intervention (PCI). The current study is designed to evaluate the effectiveness and safety of Sequential Therapy of Atorvastatin in patients with ST-elevated myocardial infarction and receive PCI treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
1,200
80mg atorvastatin before PPCI and 40mg/d for 7 days after PPCI
Ruijin Hospital, Dept. of Cardiology
Shanghai, Shanghai Municipality, China
Major Adverse Events (MACE) Occourance Rate
1. Cardiac Death (CD) 2. Non-fatal re-inarction (CK-MB, cTNI or cTNT elevation again and over 3 times higher than up normal limit accompanied with syptoms or EKG indication) 3. revascularization driven by syptoms (CABG or re-PCI)
Time frame: 30 days
Secondary Endpoints
1. TMP and TIMI grade chage after stents implantation; EKG ST reduction 2. MACE ( same definition as primary endpoints)
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.